Progress data according to Pathological reports

(Biochemical tests)

Urine Examination	Renal – Profile
Blood Sugar	Lipid Profile

Urine Examination

No. of patients - 410
Male - 273
Female - 137
Age - 47 ±12
Marital Status - Married - 356, Unmarried -54
Exercise –

• Regular - 139
• Irregular -196
• Often - 75

Avg. Body Weight - 66 kg ± 10 kg
Duration of Diabetes - 16 yrs ± 4.5 yrs

Physical
	Initial	3 weeks	8 weeks	12 weeks	16 weeks
Appearance	Turbid	Mild turbid	Clear	Clear	Clear
Deposits	Present	Present	Absent	Absent	Absent
Reaction	Acidic	Acidic	Acidic	Acidic	Acidic

Chemical
	Initial	3 weeks	8 weeks	12 weeks	16 weeks
Albumin	trace	Clear	Clear	Clear	Clear
	1+	Faint trace	Clear	Clear	Clear
	2+	2+	1+	Trace	Clear
	3+	2+	1+	Trace	Clear
	4+	3+	2+	2+	Trace
Sugar	trace	nil	nil	nil	nil
	1+	nil	nil	nil	nil
	2+	1+	nil	nil	nil
	3+	1+	trace	nil	nil
	4+	2+	nil	nil	nil
Acetone	Present	nil	nil	nil	nil
Bile salt	Present	nil	nil	nil	nil
Bile pigments
Other
Calcium oxalate	Present	nil	nil	nil	nil
n=6
Triple Phosphate	Present	nil	nil	nil	nil
n=4

Top

Renal - Profile

No. of Patients - 118
Male - 78
Female - 40
Age - 57 (±12)
Marital Status - Married - 107, Unmarried - 011
Avg. body weight - 66 kg ( ± 10 kg)
Duration of Diabetes - 16 yrs (± 6 yrs)
Exercise –

• Regular - 46
• Irregular -53
• Often - 19

Micral (Micro-Albumin Test)
In microgram	3 weeks	8 weeks	12 weeks	16 weeks
Gp I 49.30± 9.50	33.52 ± 6.8	20.10 ± 7.2	Not detectable	Not detectable
Gp II 89.30± 9.50	68.76 ± 6.8	49.50 ± 7.2	40.50± 6.2	Not detectable
Gp III 89.30± 9.50	68.76 ± 6.8	49.50 ± 7.2	40.50± 6.2	Not detectable

n = 94
Male - 63
Female - 31

Urea
	Previous	3 weeks	8 weeks	12 weeks	16 weeks
Gp I	67.80 ± 8.2	60.03 ± 5.8	49.48 ± 4.6	43.40± 4.40	36.16± 4.87
Gp II	106.3 ±9.3	92.48 ± 6.3	77.68 ± 4.8	69.90± 5.60	57.32± 6.30
Gp III	178.6 ±13.2	157.16 ± 8.5	133.53 ± 7.7	114.84± 6.7	93.20± 10.7

Creatinine
	Previous	3 weeks	8 weeks	12 weeks	16 weeks
Group I	2.8 ± 0.9	2.25 ± 0.60	1.98 ± 0.80	1.80± 0.9	1.60± 0.70
Group II	7.6 ± 1.2	6.99 ±0.97	6.08 ± 0.70	5.40± 0.60	3.93± 0.66
Group III	11.2 ±1.6	9.96 ± 1.10	8.67 ± 08.0	7.28± 0.70	6.25± .09

Top

Blood Sugar

No. of Patients - 1367
Male - 940
Female - 427
Age - 58 (±30)
Marital Status - Married – 1192, 159 – Unmarried, 016 – Widowed Divorced
Avg. Body Weight - 68 kg ( ± 22 kg)
Duration of Diabetes - 20 yrs (± 17 yrs)
Exercise –

• Regular - 182
• Irregular -300
• Often - 885

	Previous	3 weeks	8 weeks	12 weeks	16 weeks
Fasting	170±27	144.5±14	125.28±12	112.6±12	98.8±09
PP	287±35	260.80±22	219.90±23	162.70±19	118.8±16

C-Peptide
3 weeks	8 weeks	12 weeks	16 weeks
1.10±.93			2.54±0.9
Insulin Assay
3 weeks	8 weeks	12 weeks	16 weeks
4.90±3.0			09.20±5.30
GHb %
3 weeks	8 weeks	12 weeks	16 weeks
9.30±2.4		6.7±0.8	6.5±0.9

Top

Lipid Profile

No. of Patients - 297
Male - 172
Female - 125
Age -
Marital Status - Married – 297, Unmarried, Widowed & Divorced -No
Avg. Body Weight - 68 kg ( ± 11.5 kg)
Duration of Diabetes - 16 yrs (± 8 yrs)
Exercise –

• Regular - 143
• Irregular -113
• Often - 041

	3 weeks	8 weeks	12 weeks	16 weeks
Total Cholestrol	240±30			188±25
HDL	42±11			56±12
Trigyceride	295±40			172±22
VLDL	78±21			46±14
LDL	112±34			96±21
Systolic BP	150±12			118±14
Diastolic BP	92±8			84±6

Base line characteristics of uncontrolled type 2 Diabetes receiving treatment that include twice /thrice daily Glybenclamide/Gliclazide –80mg Glipizide/Glimipride/Gliclazide-80mg Glipizide /Glimipride - 2 mg  Metformin/Pioglitazone/Rosiglitazone
Treatment -
Group I
                 Glybenclamide + Metformin
                 Glipizide + Metformin
                 Glyclazide + Metformin
                 Glimipride + Metformin
GroupII
                 Glybenclamide + Metaformin + Pioglitazone
                 Glipizide + Metaformin + Pioglitazone
                 Gliclazide + Metaformin + Pioglitazone
                 Glimipride + Metaformin + Pioglitazone
Group III
                 Gliclazide + Metaformin + Rosiglitazone
Group IV
                  Human mixtard
                  Human mixtard +  Metformin
                  Human  mixtard + Metformin + Gliclazide

• By changing life style and adding herbal preparations clinical and pathological findings are evaluated.
• This is a primary work and can be varied on multicentric trails because as per ancient concept Desh (Geographical region) Kala(Time and seasons) Bala(individual immunity and strength) may vary the results.
• For example if we repeat this study in costal area the variation in Blood Sugar (reducing)level is ±24 mg % & LDL level remain unchanged while trigyceride and cholestrol level may vary up to 15 mg%

Top

Progress data according to General information
Progress data according to Symptoms